News from Bayer
September 08, 2022
Not intended for U.S. and UK Media
Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients
September 02, 2022
Not intended for U.S. and UK Media
Kerendia™ (finerenone) receives updated label in the U.S. to include findings from Phase III FIGARO-DKD cardiovascular outcomes study
September 01, 2022
Kimberly Mathisen appointed to the Supervisory Board of Bayer AG